# Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

> **NCT00648999** · PHASE4 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 207 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** lopinavir/ritonavir

## Key facts

- **NCT ID:** NCT00648999
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2013-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648999, "Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00648999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*